Evidence map›Paper›PMID 37484262›Full record

ArticleHeliyon2023

Mechanistic insight into the bioactivity of prodigiosin-entrapped lipid nanoparticles against triple-negative breast, lung and colon cancer cell lines.

Thaddeus H Gugu, Christopher O Eze, Franklin C Kenechukwu, Muhammd A Khumaini Mudhar Bintang, Sanjay B Patil, Ganesh D Basarkar, Anthony A Attama, Emmanuel C Ibezim, Chandrashekhar D Upasani, Teerapol Srichana

RetractedOpen access · goldAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Thaddeus H GuguDepartment of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka. Enugu State, Nigeria.
Christopher O EzeDepartment of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka. Enugu State, Nigeria.
Franklin C KenechukwuDepartment of Pharmaceutics, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka. Enugu State, Nigeria.
Muhammd A Khumaini Mudhar BintangDrug Delivery System Excellence Center, Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Songkhla 90112, Thailand.
Sanjay B PatilDepartment of Pharmaceutics, SNJB's Shriman Sureshdada Jain College of Pharmacy, Chandwad, Savitribai Phule Pune University, Pune. (MS), India.
Ganesh D BasarkarDepartment of Pharmaceutics, SNJB's Shriman Sureshdada Jain College of Pharmacy, Chandwad, Savitribai Phule Pune University, Pune. (MS), India.
Anthony A AttamaDepartment of Pharmaceutics, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka. Enugu State, Nigeria.
Emmanuel C IbezimDepartment of Pharmaceutics, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka. Enugu State, Nigeria.
Chandrashekhar D UpasaniDepartment of Pharmacology and Toxicology, SNJB's Shriman Sureshdada Jain College of Pharmacy, Chandwad, Savitribai Phule Pune University, Pune. (MS), India.
Teerapol SrichanaDrug Delivery System Excellence Center, Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Songkhla 90112, Thailand.
University of Nigeria · NGPrince of Songkla University · THSavitribai Phule Pune University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This research investigates the potentials of prodigiosin

Indexed as

And colon cancerCancer cell linesLung cancerParenteral nanoparticles (PNPs)Serratia marcescens, prodigiosin (PG)Triple-negative breast cancer (TNBC)

Identifiers

PMID37484262
PMCPMC10361034
OpenAlexW4380208105

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.